Announcements Trials
Browse Landscape

Phase

Phase 2 144Phase 3 65Phase 1 55Phase 1/2 34Phase 4 8Phase EARLY_PHASE1 2Phase NA 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

HR Positive HER2 Negative Advanced Breast Cancer 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1Advanced HR - Positive, HER2 - Negative Breast Cancer 1Advanced Breast Cancer 1

Interventions

Exercise 112Surveys and Questionnaires 55Early Intervention, Educational 49Methods 46Standard of Care 45Magnetic Resonance Spectroscopy 45Blood Specimen Collection 44Acupuncture Therapy 44Educational Status 43Radiotherapy 36Mammography 36Control Groups 31Therapeutics 29Counseling 29Psychiatric Rehabilitation 27Cyclophosphamide 27Sentinel Lymph Node Biopsy 25Biopsy 24Yoga 20Mastectomy, Segmental 20Resistance Training 19Palliative Care 18Neoadjuvant Therapy 18High-Energy Shock Waves 18Doxorubicin 18Cognitive Behavioral Therapy 18Magnetic Resonance Imaging 17Practice Guidelines as Topic 16Paclitaxel 16Trastuzumab 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Breast Neoplasms × Fulvestrant × Clear all
NCT00126464 2013-11-06

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

National Cancer Institute (NCI)

Phase NA Unknown
100 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡